Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
ENTX
Entera Bio Ltd.
Entera Bio develops peptide therapeutics (EB613, EB612, OPK-88006) and related oral peptide programs.
|
$58.70M |
$1.27
+6.25%
|
|
YI
111, Inc.
Private label medical devices and biometrics offerings under the healthcare product lineup.
|
$58.60M |
$6.71
+0.67%
|
|
MDAI
Spectral AI, Inc.
DeepView is a diagnostic imaging device used to detect and manage wounds, fitting Diagnostic Equipment.
|
$58.00M |
$1.90
+0.53%
|
|
ICCC
ImmuCell Corporation
The company develops immunology-based therapeutics for animal health, including passive immunity and antimicrobial approaches used in calves and dairy cows.
|
$57.44M |
$6.25
-1.50%
|
|
QTTB
Q32 Bio Inc.
Bempikibart is a fully human monoclonal antibody targeting IL-7Rα, a core monoclonal antibody therapeutic category.
|
$57.33M |
$4.71
+3.74%
|
|
NSPR
InspireMD, Inc.
InspireMD's core products are vascular/interventional endovascular devices (carotid stent systems with embolic protection).
|
$57.20M |
$1.34
-0.74%
|
|
EHTH
eHealth, Inc.
eHealth's core business is to facilitate enrollment in health insurance products (Medicare and other plans).
|
$56.61M |
$1.84
+2.22%
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Core antibody discovery platform offering de novo antibody design and epitope mapping via LENSai/HYFT.
|
$56.31M |
N/A
|
|
ACRV
Acrivon Therapeutics, Inc. Common Stock
Companion Diagnostics: The company develops the OncoSignature companion diagnostic to identify patients likely to respond to its therapies.
|
$56.17M |
$1.77
+6.29%
|
|
MGX
Metagenomi, Inc. Common Stock
MGX's core platform is gene therapy/gene editing tools enabling therapeutic gene modification, including in vivo MGX-1.00 programs.
|
$55.57M |
$1.48
+2.78%
|
|
STSS
Sharps Technology, Inc.
Core product category: Safety syringes (SafeGard/Sologard) with passive safety features.
|
$53.91M |
$1.91
-0.52%
|
|
ACTU
Actuate Therapeutics Inc
Actuate Therapeutics is a biotech company focused on oncology with a lead product elraglusib (a GSK-3β inhibitor).
|
$53.69M |
$2.29
+6.74%
|
|
KZR
Kezar Life Sciences, Inc.
AIH is an immune-mediated liver disease and zetomipzomib is an immunomodulatory small molecule in development by Kezar.
|
$53.68M |
$7.33
-0.47%
|
|
KRON
Kronos Bio, Inc.
Kronos Bio's core activity is oncology-focused biotechnology with a pipeline of small-molecule oncology agents, fitting Biotech - Oncology.
|
$53.65M |
$0.88
|
|
MREO
Mereo BioPharma Group plc
Mereo's core focus is developing therapeutics for rare diseases, fitting the Biotech - Rare Diseases category.
|
$53.56M |
$0.33
+2.64%
|
|
AAME
Atlantic American Corporation
Bankers Fidelity provides health insurance products (Medicare supplement and group health), expanding L&H offerings.
|
$53.13M |
$2.44
-6.70%
|
|
SCLX
Scilex Holding Company
Core business focused on non-opioid pain management drugs and a pipeline of non-opioid therapies.
|
$52.34M |
$6.81
+3.34%
|
|
ECOR
electroCore, Inc.
Directly markets and sells neuromodulation medical devices (gammaCore, Quell, Truvaga, Sparrow Ascent, TAC-STIM).
|
$51.97M |
$6.45
-3.44%
|
|
NBY
NovaBay Pharmaceuticals, Inc.
Directly manufactures wound care devices which are the sole continuing reportable product line (export to China).
|
$51.92M |
$1.96
+0.26%
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$51.75M |
$4.08
-0.37%
|
|
LINK
Interlink Electronics, Inc.
Medical devices & biometrics is a target end-market for Interlink’s sensor and printed electronics solutions.
|
$50.24M |
$3.27
+7.21%
|
|
ATOS
Atossa Therapeutics, Inc.
Atossa is a clinical-stage biotech focused on oncology with Z-endoxifen as its lead cancer therapy candidate.
|
$50.20M |
$5.90
+2.25%
|
|
CDIX
Cardiff Lexington Corporation
Nova Ortho & Spine provides diagnostic and related assessment services, aligning with Diagnostics & Lab Services in Healthcare.
|
$50.18M |
$3.44
|
|
ARAY
Accuray Incorporated
Accuray's CyberKnife and TomoTherapy/Radixact systems rely on advanced medical imaging for planning and guidance.
|
$50.06M |
$0.44
-1.12%
|
|
TELO
Telomir Pharmaceuticals, Inc. Common Stock
Telomir-1 is described as an oral small molecule therapeutic candidate, directly matching the 'Oral Small Molecule Therapeutics' tag.
|
$49.85M |
$1.46
+8.96%
|
|
PRPO
Precipio, Inc.
Pathology/clinical lab services and diagnostic testing operations.
|
$49.58M |
$28.43
-1.97%
|
|
ANVS
Annovis Bio, Inc.
The lead candidate Buntanetap is positioned as an Alzheimer's disease (AD) therapeutics program with cognition endpoints and an FDA-aligned path toward NDA filings.
|
$49.56M |
$1.89
+5.90%
|
|
EDSA
Edesa Biotech, Inc.
EB06 is an anti-CXCL10 monoclonal antibody therapeutic directly developed by Edesa for vitiligo, representing a direct monoclonal antibody product.
|
$49.42M |
$5.92
+15.27%
|
|
DRIO
DarioHealth Corp.
Integrated Medical Devices & Biometrics (smart glucose meters and biofeedback sensors) are part of the offering.
|
$49.14M |
$7.19
+2.28%
|
|
OSTX
OS Therapies Incorporated
OSTX's lead therapy OST-HER2 is a cancer immunotherapy targeting oncology indications.
|
$48.95M |
$1.39
-1.07%
|
|
CPIX
Cumberland Pharmaceuticals Inc.
Caldolor is a non-opioid IV analgesic, aligning CPIX with non-opioid pain management products.
|
$48.31M |
$3.25
+5.18%
|
|
CUE
Cue Biopharma, Inc.
CUE Biopharma is developing oncology-focused immunotherapies and cancer programs, aligning with Biotech - Oncology.
|
$47.73M |
$0.61
-1.43%
|
|
NERV
Minerva Neurosciences, Inc.
Minerva focuses on neuropsychiatric drug development (roluperidone for schizophrenia negative symptoms).
|
$47.07M |
$6.73
+7.00%
|
|
SCYX
SCYNEXIS, Inc.
SCYNEXIS's ibrexafungerp is a lead oral small-molecule therapeutic, fitting the 'Oral Small Molecule Therapeutics' category.
|
$46.58M |
$1.10
+4.76%
|
|
IBIO
iBio, Inc.
The company markets and utilizes an Antibody Discovery Platform (epitope-steering AI, StableHu, EngageTx, ShieldTx) to identify and optimize antibody candidates.
|
$46.32M |
$2.06
-2.61%
|
|
HOWL
Werewolf Therapeutics, Inc.
Platform-focused immune-modulating therapies and immuno-oncology programs fit Immunology Therapeutics.
|
$45.90M |
$0.94
+2.62%
|
Showing page 28 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
